Literature DB >> 24405558

Non-ST-elevation myocardial infarction with the use of oxymetazoline nasal spray.

Saurabh Rajpal1, Liam A Morris2, Nuri I Akkus2.   

Abstract

Oxymetazoline is an alpha-1 adrenergic receptor agonist that is commonly used for nasal decongestion and is readily available without a prescription. We report the case of a 64-year-old woman who developed prolonged chest pain associated with elevation of cardiac biomarkers after using oxymetazoline.
Copyright © 2013 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Keywords:  Enfarte do miocárdio sem supradesnivelamento de ST; Non-ST-elevation myocardial infarction; Oximetazolina spray nasal; Oxymetazoline nasal spray

Mesh:

Substances:

Year:  2014        PMID: 24405558     DOI: 10.1016/j.repc.2013.07.011

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  3 in total

1.  Effect of Intranasal Vasoconstrictors on Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Shawna D Bellew; Katie L Johnson; Micah D Nichols; Tobias Kummer
Journal:  J Emerg Med       Date:  2018-09-06       Impact factor: 1.484

2.  Myocardial infarction and ischemic stroke with vasoconstrictors used as nasal decongestant for common cold: a French pharmacovigilance survey.

Authors:  Margaux Lafaurie; Pascale Olivier; Charles Khouri; Marina Atzenhoffer; Kévin Bihan; Geneviève Durrieu; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2019-12-20       Impact factor: 2.953

3.  Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study.

Authors:  Lamiae Grimaldi-Bensouda; Bernard Begaud; Jacques Benichou; Clementine Nordon; Olivia Dialla; Nicolas Morisot; Yann Hamon; Yves Cottin; Elie Serrano; Lucien Abenhaim; Emmanuel Touzé
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.